mitochondria targeting
Recently Published Documents


TOTAL DOCUMENTS

432
(FIVE YEARS 204)

H-INDEX

44
(FIVE YEARS 12)

Drug Delivery ◽  
2022 ◽  
Vol 29 (1) ◽  
pp. 270-283
Author(s):  
Akula S. N. Murthy ◽  
Sanket Das ◽  
Tejinder Singh ◽  
Tae-Wan Kim ◽  
Nasim Sepay ◽  
...  

Author(s):  
Dulal Musib ◽  
Vanitha Ramu ◽  
Md Kausar Raza ◽  
Aarti Upadhyay ◽  
Maynak Pal ◽  
...  

Red light-activable transition metal complexes have recently emerged as the viable alternative for photodynamic/photochemotherapeutic applications. Ideal photosensitizers or photochemotherapeutic agents are still an elusive goal. Here in, we have reported...


2022 ◽  
Vol 26 (1) ◽  
pp. 15-24
Author(s):  
Yoonhee Bae ◽  
Goo-Young Kim ◽  
Flores Jessa ◽  
Kyung Soo Ko ◽  
Jin Han

2021 ◽  
Vol 23 (1) ◽  
pp. 112
Author(s):  
Takao Tsujioka ◽  
Daisuke Sasaki ◽  
Atsuhito Takeda ◽  
Hideyoshi Harashima ◽  
Yuma Yamada

The development of drug delivery systems for use in the treatment of cardiovascular diseases is an area of great interest. We report herein on an evaluation of the therapeutic potential of a myocardial mitochondria-targeting liposome, a multifunctional envelope-type nano device for targeting pancreatic β cells (β-MEND) that was previously developed in our laboratory. Resveratrol (RES), a natural polyphenol compound that has a cardioprotective effect, was encapsulated in the β-MEND (β-MEND (RES)), and its efficacy was evaluated using rat myocardioblasts (H9c2 cells). The β-MEND (RES) was readily taken up by H9c2 cells, as verified by fluorescence-activated cell sorter data, and was observed to be colocalized with intracellular mitochondria by confocal laser scanning microscopy. Myocardial mitochondrial function was evaluated by a Seahorse XF Analyzer and the results showed that the β-MEND (RES) significantly activated cellular maximal respiratory capacity. In addition, the β-MEND (RES) showed no cellular toxicity for H9c2 cells as evidenced by Premix WST-1 assays. This is the first report of the use of a myocardial mitochondria-targeting liposome encapsulating RES for activating mitochondrial function, which was clearly confirmed based on analyses using a Seahorse XF Analyzer.


2021 ◽  
Vol 240 ◽  
pp. 24-30
Author(s):  
Kai Hu ◽  
Lidan Xiao ◽  
Longjiang Li ◽  
Yi Shen ◽  
Yongqiang Yang ◽  
...  

Author(s):  
Tingting Hu ◽  
Zhou Qin ◽  
Chao Shen ◽  
Han-Lin Gong ◽  
Zhi-Yao He

Mitochondria, a kind of subcellular organelle, play crucial roles in cancer cells as an energy source and as a generator of reactive substrates, which concern the generation, proliferation, drug resistance, and other functions of cancer. Therefore, precise delivery of anticancer agents to mitochondria can be a novel strategy for enhanced cancer treatment. Mitochondria have a four-layer structure with a high negative potential, which thereby prevents many molecules from reaching the mitochondria. Luckily, the advances in nanosystems have provided enormous hope to overcome this challenge. These nanosystems include liposomes, nanoparticles, and nanomicelles. Here, we summarize the very latest developments in mitochondria-targeting nanomedicines in cancer treatment as well as focus on designing multifunctional mitochondria-targeting nanosystems based on the latest nanotechnology.


Sign in / Sign up

Export Citation Format

Share Document